Safety and efficacy of vemurafenib in end stage renal failure

Area of Science:

• Oncology
• Pharmacology
• Nephrology

Background:

• Serine-threonine kinase inhibitors like vemurafenib are increasingly used in cancer therapy.
• Balancing toxicity and therapeutic benefit is crucial during cancer treatment.

Observation:

• A patient with metastatic melanoma and end-stage renal failure on peritoneal dialysis received vemurafenib.
• Imaging revealed a substantial response after five months, but treatment was paused due to QTc interval prolongation (CTC grade 3).
• Vemurafenib was restarted at a reduced dose after QTc normalization, with continued significant response.

Findings:

• This is the first reported case of vemurafenib use in a patient with end-stage renal failure.
• Asymptomatic QTc prolongation was successfully managed through dose reduction.
• The patient experienced a significant treatment response over 12 months.

Implications:

• Highlights the importance of vigilant QTc interval monitoring in patients on vemurafenib, especially those with renal impairment.
• Demonstrates the feasibility of managing vemurafenib-induced QTc prolongation with dose adjustments.
• Suggests vemurafenib can be a viable treatment option for metastatic melanoma in patients with end-stage renal failure under careful monitoring.